America Is About to Go Over a Peptide Cliff

The recent vote by the Pharmacy Compounding Advisory Committee has sent shockwaves through the medical community. The committee recommended that compounding pharmacies be allowed to make and sell BPC-157, a peptide with a devoted following among some advocates for alternative medicine.

At its core, the debate over BPC-157 centers on safety and efficacy. Despite its popularity, there is little concrete evidence to support claims that it can treat everything from sore muscles to traumatic brain injuries. In fact, FDA researchers have pointed out that the scientific data on BPC-157 is surprisingly weak, and what sequence of amino acids the peptide actually contains remains unclear.

The committee’s decision reflects a broader trend in the medical industry: the growing influence of telehealth companies and wellness clinics on regulatory policy. Prominent figures like Robert F. Kennedy Jr., who has publicly expressed his enthusiasm for peptides in general and BPC-157 in particular, have significant weight in FDA advisory committees.

Telehealth companies such as Hims & Hers and Noom have been vocal advocates for allowing American companies to sell BPC-157, arguing that doing so would create a safer and more transparent market. However, this argument is problematic. As Brian Lee, an associate professor of clinical medicine at USC, pointed out in a dissenting vote, the decision could create a perception that BPC-157 has the FDA’s implicit approval – which would be a concerning precedent.

The implications of this decision go beyond just the peptide itself. If the FDA allows compounding pharmacies to make and sell these treatments without rigorous testing or oversight, it will set a troubling precedent for the regulation of other emerging therapies. It could also create a profit-driven gold rush in the medical industry, where companies prioritize sales over safety.

This decision is not just about BPC-157 – it’s about the future of medical regulation and the priorities of our regulatory agencies. As we move forward, it’s essential that we keep a close eye on these developments and demand more transparency from our regulators. The FDA still has to sign off on an actual rule change, but given Kennedy’s demonstrated enthusiasm for peptides, ultimate approval seems likely.

The real question is not what BPC-157 can do for our bodies, but rather what it says about the values and priorities of our regulatory agencies. As this story continues to unfold, one thing is clear: we need a more nuanced conversation about the role of the FDA in regulating emerging therapies – and a closer look at who’s influencing these decisions.